vTv Therapeutics (VTVT) Reports Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Tweet Send to a Friend
vTv Therapeutics Inc. (NASDAQ: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE